Joshua Brody, Director of Lymphoma Immunotherapy Program at Icahn School of Medicine at Mount Sinai, shared a post on LinkedIn:
“Quick chat with Lymphoma Hub on bispecifics for mantle cell lymphoma and the recent phase III frontMIND for DLBCL both real victories for immunotherapy and for patients!
Read the Full Article here.”